1. Salivary Amylase: Digestion and Metabolic Syndrome

   • Catherine Peyrot des Gachons
   • Paul A. S. Breslin

   Obesity (J McCaffery, Section Editor) 17 September 2016 Article: 102

2. Viral Hepatitis and Diabetes: Clinical Implications of Diabetes Prevention Through Hepatitis Vaccination

   • Rudruidee Karnchanasorn
   • Horng-Yih Ou
   • Ken C. Chiu

   Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (C Shay and B Conway, Section Editors) 13 September 2016 Article: 101

3. Receptor for Advanced Glycation End Products (RAGE) in Type 1 Diabetes Pathogenesis

   • Sherman S. Leung
   • Josephine M. Forbes
   • Danielle J. Borg

   Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor) 09 September 2016 Article: 100

   

4. Surgery for Diabetic Eye Complications

   • María H. Berrocal
   • Luis A. Acaba
   • Alexandra Acaba

   Microvascular Complications—Retinopathy (JK Sun and PS Silva, Section Editors) 09 September 2016 Article: 99

   

5. Academic Detailing in Diabetes: Using Outreach Education to Improve the Quality of Care

   • Michael A. Fischer

   Health Care Delivery Systems and Implementation in Diabetes (EB Morton-Eggleston and ME McDonnell, Section Editors) 01 September 2016 Article: 98

   

6. Immune Intervention and Preservation of Pancreatic Beta Cell Function in Type 1 Diabetes

   • Kimber M. Simmons
   • Peter A. Gottlieb
   • Aaron W. Michels

   Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor) 25 August 2016 Article: 97

   

7. Taking Telemedicine to the Next Level in Diabetes Population Management: a Review of the Endo ECHO Model

   • Matthew F. Bouchonville
   • Margaret M. Paul
   • Sanjeev Arora

   Health Care Delivery Systems and Implementation in Diabetes (EB Morton-Eggleston and ME McDonnell, Section Editors) 22 August 2016 Article: 96

   

8. Biomarkers of β-Cell Stress and Death in Type 1 Diabetes

   • Raghavendra G. Mirmira
   • Emily K. Sims
   • Carmella Evans-Molina

   Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor) 19 August 2016 Article: 95

9. What Are We Learning from the FDA-Mandated Cardiovascular Outcome Studies for New Pharmacological Antidiabetic Agents?

   • Dragana Lovre
   • Wynn Htun
   • Vivian A. Fonseca

   Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors) 19 August 2016 Article: 94

10. Diet and Gut Microbial Function in Metabolic and Cardiovascular Disease Risk

    • Katie A. Meyer
    • Brian J. Bennett

    Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (C Shay and B Conway, Section Editors) 19 August 2016 Article: 93

11. SGLT2 Inhibitors: Benefit/Risk Balance

    • André J. Scheen

    Pharmacologic Treatment of Type 2 Diabetes (HE Lebovitz and G Bahtiyar, Section Editors) 19 August 2016 Article: 92

    

12. Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes

    • Scott J. Pilla
    • Amy Q. Quan
    • Nestoras N. Mathioudakis

    Diabetes Epidemiology (N Maruthur, Section Editor) 15 August 2016 Article: 91

13. Fenofibrate and Diabetic Retinopathy

    • Jared E. Knickelbein
    • Akshar B. Abbott
    • Emily Y. Chew

    Microvascular Complications—Retinopathy (JK Sun and PS Silva, Section Editors) 15 August 2016 Article: 90

14. The Role of the Intestinal Microbiome in Type 1 Diabetes Pathogenesis

    • James C. Needell
    • Danny Zipris

    Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor) 15 August 2016 Article: 89